The Congressional Budget Office on Thursday (Feb. 4) revealed it relied heavily on metrics long opposed by drug makers and patient advocates to estimate the budget impact of Medicare price negotiation in House Democrats’ H.R. 3. The CBO paper is an indication of how powerful the Institute for Clinical & Economic Review could become if the government moves to a system that sets prices for drugs based on their value to the health care system. In 2019, CBO estimated that...